ONCY appoints Patricia S. Andrews to Board of DirectorsPatricia S. Andrews, Chief Executive Officer and Global Head of Oncology, Sumitomo Pharma Oncology
Sumitomo Pharma Oncology, Inc., a wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced today that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sunovion Pharmaceuticals Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.
"Sumitomo Pharma America represents an exciting opportunity to leverage each subsidiary's competitive strengths to create an innovative biopharma company with the scale, agility and efficiency needed for accelerated impact and patient-focused outcomes," said Myrtle Potter, current CEO of Sumitovant and future President and CEO of Sumitomo Pharma America.
Sumitovant is a technology-driven biopharmaceutical company accelerating development and commercialization of new potential therapies for patients with rare conditions and other diseases.
"Sumitomo Pharma America will be well positioned to accelerate the development of Sumitomo Pharma Oncology's portfolio, and address unmet needs for cancer patients," said Patricia S. Andrews, Chief Executive Officer and Global Head of Oncology, Sumitomo Pharma Oncology.
https://www.prnewswire.com/news-releases/sumitomo-pharma-subsidiary-companies-in-the-us-including-sumitomo-pharma-oncology-to-combine-and-form-sumitomo-pharma-america-301788413.html